Back to the overview page

Annelies (AW) Turksma PhD

Department
Immunopathology
E-mail
a.turksma@sanquin.nl
LinkedIn
http://nl.linkedin.com/pub/annelies-turksma/46/b49/8b0
Training

Biomedical Sciences and Oncology

Research interests
Immunomonitoring, immunotherapy
Technology
  • Flow Cytometry
  • Cell culture (moDC, T cell)
  • B cell culture and tumor cell lines)
  • Westernblot
  • ELIspot
  • ELISA
  • Designing DNA constructs
  • DNA and RNA isolation
  • In vitro mRNA transcription
  • mRNA transfections
  • Viral transfections
  • Immunohistochemistry
Resume
2014-present Post-doc fellow at the Dept of Immunopathology, Sanquin Research, Amsterdam
2007-2013 PhD, Tumour Immunology, VU University medical centre, Amsterdam
2006 Internship, University of Edinburgh, Edinburgh, DNA Repair and Cancer Research Group
Subject: ERCC1 and UV sensitivity in keratinocytes
2005 Internship, VU University Medical Center, Amsterdam, Department of Otolaryngology
Subject: Genetic factors in head and neck cancer
2004 Internship, VU University Medical Center, Amsterdam, Department of Medical Oncology
Subject: thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism
2004-2007 Master Oncology, VU University medical centre, Amsterdam
2000-2004 Bachelor Biomedical sciences, VU University, Amsterdam
Publications
Sanquin publications
Other publications

Turksma AW, Bontkes HJ, Ruizendaal JJ, Moesbergen L, de Gruijl TD, Leemans CR, Bloemena E, Meijer CJLM, Hooijberg E. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med 2013; 11:152.

Santegoets SJAM, Turksma AW, Powell Jr. DJ, Hooijberg E, de Gruijl TD. IL-21 in cancer immunotherapy: at the right place at the right time. Oncoimmunology 2013; 2(6):e24522.

Turksma AW, Bontkes H, Ruizendaal JJ, van den Heuvel H, Scholten KBJ, Santegoets SJAM, de Gruijl TD, Bloemena E, Meijer CJLM, Hooijberg E. Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells. Hum Immunol 2013; 74(5):506-13.

Santegoets SJ1, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, Powell DJ Jr, June CH, de Gruijl TD. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med 2013; 11:37.

Turksma AW, Braakhuis B, Bloemena E, Leemans CR, Hooijberg E. Immunotherapy in HNSCC patients, shifting the balans. Immunotherapy 2013; 5(1):49-61.

Turksma AW, Bontkes HJ, van den Heuvel H, de Gruijl TD, von Blomberg BME, Braakhuis BJM, Leemans CR, Bloemena E, Meijer CJLM, Hooijberg E. Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis 2013; 19(6):577-84.

Turksma AW*, de Weger VA*,  Voorham QJ*, Euler Z*, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken JB, Van Tinteren H, Meijer GA, Hooijberg E. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res 2012; 18(3):882-9. (* these authors contributed equally)

Scholten KB, Turksma AW, Ruizendaal JJ, van den Hende M, van der Burg SH, Heemskerk MH, Meijer CJ, Hooijberg E. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med 2011; 9:147.

Temmink OH, de Bruin M, Turksma AW, Cricca S, Laan AC, Peters GJ. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int J Biochem Cell Biol 2007; 39(3):565-75.

Temmink OH, de Bruin M, Laan AC, Turksma AW, Cricca S, Masterson AJ, Noordhuis P, Peters GJ. The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells. Int J Biochem Cell Biol 2006; 38(10):1759-65.

Last edited on: 4 May 2016
Back to the overview page